Terremoto Biosciences, a pioneering biotechnology company at the forefront of developing novel therapeutics targeting the PI3K/AKT pathway, announced today the successful closure of a significant $108 million Series C financing round. This substantial investment, spearheaded by a consortium of leading life sciences investors, including Novo Holdings, OrbiMed, Third Rock Ventures, RA Capital Management, Cormorant Asset Management, and BeOne Medicines, is poised to propel Terremoto’s innovative AKT1-selective inhibitor programs into early clinical development across a spectrum of challenging oncological and rare disease indications. The funding marks a critical inflection point for the company, enabling it to translate its groundbreaking scientific approach into tangible patient benefits.
The strategic allocation of these funds will be directed towards advancing Terremoto’s pipeline through Phase I clinical trials. A primary focus will be on oncology, with particular emphasis on hormone receptor (HR)-positive breast cancer, a persistent and significant challenge in women’s health. Concurrently, the company will advance its programs in rare diseases, including hereditary hemorrhagic telangiectasia (HHT), a debilitating inherited bleeding disorder. This dual-pronged approach underscores Terremoto’s commitment to addressing unmet medical needs across diverse patient populations.
The company’s most advanced asset in its oncology portfolio is TER-2031, a highly selective AKT1 blocker currently undergoing evaluation in a first-in-human Phase I trial (NCT07109726). This trial is meticulously designed to assess the safety and efficacy of TER-2031 in patients with solid tumors harboring specific genetic mutations within the PIK3CA, AKT, or PTEN pathways. These mutations are frequently implicated in the development and progression of various cancers, including breast, ovarian, squamous head and neck, and endometrial cancers, as detailed on ClinicalTrials.gov. The ability of TER-2031 to target these specific mutations, while potentially mitigating the off-target effects often associated with broader PI3K/AKT pathway inhibitors, represents a significant leap forward in precision oncology.
Beyond its oncology endeavors, Terremoto is gearing up to advance TER-4480, another promising AKT1 inhibitor, into clinical trials for HHT. The company aims to initiate this program later in 2026. The development of therapies for HHT holds immense significance, as there are currently no approved treatments for this inherited bleeding disorder. Affecting an estimated 1.4 million individuals globally, according to Cure HHT, HHT is the second most prevalent bleeding disorder in the United States, surpassed only by Von Willebrand disease. The absence of approved therapies creates a profound unmet need, and Terremoto’s efforts in this area could revolutionize patient care and outcomes.
H2: Addressing the Toxicity Challenges of PI3K/AKT Inhibitors
The PI3K/AKT pathway is a critical cellular signaling cascade that plays a pivotal role in cell growth, proliferation, survival, and metabolism. Its dysregulation is a common hallmark of many cancers, making it a highly attractive target for therapeutic intervention. However, the development of PI3K/AKT inhibitors has been historically hampered by significant toxicity challenges, leading to dose-limiting side effects that can compromise patient tolerability and treatment efficacy.
A recent milestone in this field was achieved in November 2023 when AstraZeneca secured approval for Truqap (capivasertib), the first AKT inhibitor to receive regulatory clearance for patients with HR-positive, HER2-negative advanced breast cancer. Truqap, a non-selective blocker of AKT1, AKT2, and AKT3, has demonstrated considerable potential in solid tumor indications and has become a key product for AstraZeneca’s oncology division. Despite its therapeutic promise, Truqap can elicit notable adverse events, including glucose dysregulation, increased susceptibility to infections, and liver toxicity. These side effects are often attributed to the inhibition of AKT2, which plays crucial roles in metabolic homeostasis and immune function.
Terremoto Biosciences’ core innovation lies in its hypothesis that the toxicity associated with current AKT inhibitors is primarily driven by the inhibition of AKT2. By developing highly selective AKT1 inhibitors, Terremoto aims to circumvent these dose-limiting toxicities. The rationale is that by specifically targeting AKT1, which is often implicated in cancer cell proliferation and survival without the same level of involvement in critical physiological processes as AKT2, a more tolerable therapeutic profile can be achieved. This selective approach could unlock the full therapeutic potential of AKT inhibition, offering a safer and more effective treatment option for patients who currently face significant side effects.
The company’s strategic focus on AKT1 selectivity is a testament to its deep understanding of the complex biology of the PI3K/AKT pathway and its commitment to developing differentiated therapeutics. This approach not only aims to improve patient outcomes in cancer but also to provide much-needed options for rare diseases where the risk-benefit profile of current treatments may be unfavorable.
H3: A Competitive Landscape and Future Outlook
Terremoto Biosciences is operating within a dynamic and competitive landscape. The pursuit of next-generation AKT inhibitors is an active area of research and development for numerous biopharmaceutical companies. For instance, Atavistik Bio is also exploring selective allosteric AKT1 inhibition, recently dosing its first subject in a Phase I trial for ATV-1601 in adults with solid tumors. This indicates a broader industry recognition of the therapeutic potential of targeting specific AKT isoforms.
According to GlobalData’s Pharmaceutical Intelligence Center, there are currently 37 ongoing clinical trials investigating AKT inhibitors across Phase I, II, and III. This robust pipeline activity highlights the intense interest and investment in this therapeutic area. The success of Terremoto’s selective AKT1 inhibitors will depend not only on their inherent efficacy and safety profiles but also on their ability to demonstrate a clear advantage over existing and emerging therapies.
The $108 million Series C funding provides Terremoto with the financial runway to navigate the critical early stages of clinical development. Successfully completing Phase I trials will be paramount in validating their scientific hypothesis and de-risking the programs for future development. The company’s ability to secure such significant investment from prominent venture capital firms and strategic investors underscores the confidence in their technology and their leadership team.
The implications of Terremoto’s success extend beyond the immediate therapeutic benefits for patients. A breakthrough in developing well-tolerated AKT inhibitors could reshape the treatment paradigms for a wide range of cancers and genetic disorders. It could also pave the way for combination therapies, where selective AKT inhibitors are used in conjunction with other targeted agents or immunotherapies to achieve synergistic effects and overcome resistance mechanisms.
The company’s commitment to rare diseases, particularly HHT, also highlights a growing trend in the pharmaceutical industry to address conditions that, while affecting fewer patients, represent significant unmet needs and can have a profound impact on quality of life. The development of the first approved therapy for HHT would be a monumental achievement, potentially setting a precedent for further innovation in other rare bleeding disorders.
The journey from preclinical research to approved therapy is long and arduous, marked by scientific challenges, regulatory hurdles, and the inherent uncertainties of clinical trials. However, with this substantial Series C funding, Terremoto Biosciences is well-positioned to advance its promising pipeline and potentially deliver transformative therapies to patients suffering from cancer and rare diseases. The biotech’s strategic focus on selective AKT1 inhibition offers a compelling pathway to overcome the historical toxicity challenges associated with this crucial signaling pathway, heralding a new era of more tolerable and effective treatments. The coming years will be critical in observing how Terremoto navigates the complexities of clinical development and realizes the full potential of its innovative scientific platform.
Leave a Reply